What are the qualifying characteristics for moderate or high-intensity statin initiation without 10-year risk calculation?

Prepare for the ACCSAP CCKE Coronary Artery Disease Test. Use flashcards and multiple choice questions, complete with hints and explanations. Ensure success on your test!

Multiple Choice

What are the qualifying characteristics for moderate or high-intensity statin initiation without 10-year risk calculation?

Explanation:
The scenario tests when you can start statin therapy without doing a 10-year ASCVD risk calculation because the condition itself signals high risk. Clinical ASCVD means you’ve already had a cardiovascular event or disease, so statins are used as secondary prevention to prevent another event and are started at high intensity. An LDL cholesterol of 190 mg/dL or higher points to severe primary hyperlipidemia (often familial) with very high ASCVD risk, which also warrants high‑intensity statin therapy. Diabetes mellitus, particularly in adults 40–75, is treated as a high-risk condition that supports initiating statins without calculating risk, typically at least moderate intensity, given the elevated baseline risk in diabetics. Taken together, these three factors identify scenarios where risk calculation isn’t needed to justify starting a moderate or high‑intensity statin, so all of the above are correct.

The scenario tests when you can start statin therapy without doing a 10-year ASCVD risk calculation because the condition itself signals high risk. Clinical ASCVD means you’ve already had a cardiovascular event or disease, so statins are used as secondary prevention to prevent another event and are started at high intensity. An LDL cholesterol of 190 mg/dL or higher points to severe primary hyperlipidemia (often familial) with very high ASCVD risk, which also warrants high‑intensity statin therapy. Diabetes mellitus, particularly in adults 40–75, is treated as a high-risk condition that supports initiating statins without calculating risk, typically at least moderate intensity, given the elevated baseline risk in diabetics. Taken together, these three factors identify scenarios where risk calculation isn’t needed to justify starting a moderate or high‑intensity statin, so all of the above are correct.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy